Consensus Castle Biosciences, Inc.

Equities

CSTL

US14843C1053

Market Closed - Nasdaq Other stock markets 21:00:00 29/04/2024 BST			5-day change	1st Jan Change
21.53 ^USD	+5.85%		+9.79%	-0.23%

04-08	Castle Biosciences Insider Sold Shares Worth $441,853, According to a Recent SEC Filing	MT
04-04	Castle Biosciences, Inc. Announces Share New Data At the 20Th European Association of Dermato-Oncology Congress	CI

Evolution of the average Target Price on Castle Biosciences, Inc.

Price target over the last 5 years

History of analyst recommendation changes

d7d285c3.R1Rt7-9Ran1odb7gGEigvCs_Sl5b_LcfZqSTp4DY9eo.AB9V2ps3Eio-JveVaxLkz0FYfDoYsfR2AOHYnsuczawrLACgmB4kFDol5w~fc67c1506669a9b819afdc2017c18ceb

Analyst Recommendations on Castle Biosciences, Inc.

Castle Biosciences Insider Sold Shares Worth $441,853, According to a Recent SEC Filing	04-08	MT
Guggenheim Initiates Castle Biosciences With Buy Rating, $25 Price Target	12-14	MT
Castle Biosciences, Inc. Announces Data from A Single-Site, Open-Label Study Demonstrating the Consistent Impact of Idgenetix®? on Medication Response and Remission Rates in Patients with Major Depressive Disorder	11-08	CI
KeyBanc Adjusts Price Target on Castle Biosciences to $25 From $37, Maintains Overweight Rating	04/08/23	MT
BTIG Research Adjusts Castle Biosciences Price Target to $30 From $38, Maintains Buy Rating	15/06/23	MT
Scotiabank Adjusts Castle Biosciences Price Target to $33 From $54, Maintains Sector Outperform Rating	06/06/23	MT
Canaccord Genuity Adjusts Price Target on Castle Biosciences to $40 From $60, Keeps Buy Rating	06/06/23	MT
SVB Securities Adjusts Price Target on Castle Biosciences to $35 From $50, Maintains Outperform Rating	05/06/23	MT
Lake Street Adjusts Castle Biosciences' Price Target to $32 From $41, Keeps Buy Rating	05/06/23	MT
Baird Adjusts Castle Biosciences Price Target to $25 From $35, Maintains Outperform Rating	05/06/23	MT
KeyBanc Adjusts Price Target on Castle Biosciences to $37 From $40, Maintains Overweight Rating	05/05/23	MT
Baird Adjusts Price Target on Castle Biosciences to $35 From $38, Maintains Outperform Rating	04/05/23	MT
Baird Adjusts Price Target on Castle Biosciences to $38 From $42, Maintains Outperform Rating	01/03/23	MT
Scotiabank Initiates Castle Biosciences at Sector Outperform With $54 Price Target	05/01/23	MT
Baird Adjusts Castle Biosciences' Price Target to $41 From $48, Keeps Outperform Rating	03/11/22	MT
SVB Securities Adjusts Castle Biosciences' Price Target to $50 from $45, Keeps Market Outperform Rating	09/08/22	MT
Baird Adjusts Castle Biosciences' Price Target to $48 From $44, Maintains Outperform Rating	09/08/22	MT
KeyBanc Adjusts Castle Biosciences' Price Target to $40 from $90, Keeps Overweight Rating	11/05/22	MT
SVB Securities Adjusts Castle Biosciences' Price Target to $45 from $65, Keeps Outperform Rating	10/05/22	MT
Baird Adjusts Price Target on Castle Biosciences to $44 From $50, Keeps Outperform Rating	10/05/22	MT
Canaccord Genuity Adjusts Castle Biosciences Price Target to $80 From $94, Maintains Buy Rating	05/04/22	MT
Stephens Initiates Castle Biosciences With Overweight Rating, $59 Price Target	07/01/22	MT
Stephens Starts Castle Biosciences at Overweight With $59 Price Target	07/01/22	MT
SVB Leerink Adjusts Price Target on Castle Biosciences to $75 From $85, Maintains Outperform Rating	09/11/21	MT
Baird Adjusts Price Target on Castle Biosciences to $82 From $78, Keeps Outperform Rating	09/11/21	MT